Fluicell AB (DE:5J90)
FRANKFURT:5J90
Want to see DE:5J90 full AI Analyst Report?
5J90 Stock Chart & Stats
€1.29
--
Market closed
€1.29
--
Day’s Range― - ―
52-Week Range€0.67 - €2.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)94.00
Market Cap
€1.81M
Enterprise Value€16.15M
Total Cash (Recent Filing)€2.26M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta9.06
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,373,703
10 Day Avg. Volume182
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€6.35M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtA zero-debt capital structure materially reduces refinancing and interest-rate risk for a small biotech. This durable strength preserves financial optionality, making future equity raises or strategic investments less constrained by fixed obligations over the next several quarters.
Revenue Rebound And Commercial TractionA 124% TTM revenue rebound signals improving product adoption and demand recovery after a weak period. If sustained, this trend underpins scalable growth, supports margin improvement opportunities, and validates the commercial pathway in academic and industry markets.
Specialized Microfluidics PlatformA focused microfluidics platform for single-cell and tissue research is a durable competitive asset: specialized tech addresses high-value, sticky R&D use cases in academia and industry, creating structural demand that can sustain sales as labs and partners integrate the platform.
Bears Say
Negative Cash Flow / Cash BurnSustained negative operating and free cash flow indicates continued cash burn and reliance on external financing. This structural weakness limits the firm’s ability to self-fund growth, increases dilution risk, and constrains investment in commercialization or R&D over coming quarters.
Eroding Equity BaseDeclining shareholders' equity reflects cumulative losses that weaken the company’s capital buffer. Over time this reduces financial flexibility, makes funding more dilutive or costly, and raises the bar for achieving sustainable operations without external capital.
Persistent Unprofitability And Weak MarginsOngoing negative net income and weak margins show the business is not yet operationally self-sustaining. Without margin expansion or steady high-growth revenue, profitability risks remain and long-term viability depends on improved unit economics or continued funding.
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was €0.67 and its highest was €2.04 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is €1.81M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is May 08, 2026 which is in 7 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on Feb 20, 2026. The company reported €0.007 earnings per share for the quarter, beating the consensus estimate of N/A by €0.007.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of €0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 28.409%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in DE:5J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.